Diagnosis and management of cerebral venous thrombosis: a Scientific Statement from the American Heart Association
Cerebral venous thrombosis accounts for 0.5% to 3% of all strokes. The most vulnerable
populations include young individuals, women of reproductive age, and patients with a …
populations include young individuals, women of reproductive age, and patients with a …
Cerebral vein thrombosis: management tactics with a focus on pregnancy, the use of hormone therapy and assisted reproductive technologies
S Akinshina, V Bitsadze, J Khizroeva… - The Journal of …, 2025 - Taylor & Francis
Purpose: Cerebral vein thrombosis is a rare, life-threatening condition that has now become
more commonly diagnosed due to advancements in imaging techniques. Our purpose is to …
more commonly diagnosed due to advancements in imaging techniques. Our purpose is to …
Trends in cerebral venous thrombosis before and during the COVID-19 pandemic: Analysis of the National Inpatient Sample
Objectives We sought to provide updated incidence and trend data for cerebral venous
thrombosis (CVT) in the United States from 2016-2020, examine the impact of the COVID-19 …
thrombosis (CVT) in the United States from 2016-2020, examine the impact of the COVID-19 …
[HTML][HTML] Outcome prediction in cerebral venous thrombosis: the IN-REvASC score
Background We identified risk factors, derived and validated a prognostic score for poor
neurological outcome and death for use in cerebral venous thrombosis (CVT). Methods We …
neurological outcome and death for use in cerebral venous thrombosis (CVT). Methods We …
[HTML][HTML] Adverse events in the nervous system associated with blinatumomab: a real-world study
W Gao, J Yu, Y Sun, Z Song, X Liu, X Han, L Li… - BMC …, 2025 - pmc.ncbi.nlm.nih.gov
Background Nervous system toxicity (NST) is a frequent and serious adverse event (AE)
associated with blinatumomab, the first bispecific antibody drug targeting CD19 and CD3 …
associated with blinatumomab, the first bispecific antibody drug targeting CD19 and CD3 …
New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline
C Weimar, J Beyer-Westendorf, FO Bohmann… - … Research and Practice, 2024 - Springer
Over the last years, new evidence has accumulated on multiple aspects of diagnosis and
management of cerebral venous and dural sinus thrombosis (CVT) including identification of …
management of cerebral venous and dural sinus thrombosis (CVT) including identification of …
[HTML][HTML] Serum Levels of Ferritin, Iron, and Total Iron Binding Capacity in Cerebral Venous Sinus Thrombosis
Background: Cerebral venous sinus thrombosis (CVST) is a potentially life-threatening
condition with a wide range of clinical presentations, from localized headache (the most …
condition with a wide range of clinical presentations, from localized headache (the most …
External validation of the SI2NCAL2C score for outcomes following cerebral venous thrombosis
Objectives Prognostication for cerebral venous thrombosis (CVT) remains difficult. We
sought to validate the SI 2 NCAL 2 C score in an international cohort. Materials and methods …
sought to validate the SI 2 NCAL 2 C score in an international cohort. Materials and methods …
Canadian Stroke Best Practice Recommendations: Cerebral Venous Thrombosis, 2024
The 7 th edition of the Canadian Stroke Best Practice Recommendations (CSBPR) is a 34
comprehensive summary of current evidence-based recommendations, appropriate for use …
comprehensive summary of current evidence-based recommendations, appropriate for use …
Neurovascular complications of antiphospholipid syndrome: a narrative review
GNN Mendes, ABCG de Morais… - Arquivos de Neuro …, 2024 - thieme-connect.com
Background Antiphospholipid syndrome (APS) is a systemic autoimmune disorder
characterized by thrombosis, pregnancy complications, and other nonthrombotic …
characterized by thrombosis, pregnancy complications, and other nonthrombotic …